Home2020-05-21T13:12:50+00:00

RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to sell shares; the loss of the value of investment; and dilution of shareholding. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read full risk warnings.

View our deals

Elasmogen Ltd.

Discovering and developing soloMER™s for the treatment of auto-immune mediated, inflammatory diseases.

.

  • Sector: Drug discovery and Biopharma 

  • Region: UK: Scotland

  • Stage: Growth

  • Eligible Tax: EIS

  • Funding: £2,000,218

  • Status: LIVE

57% Funded
READ MORE

Hurricane Modular Commerce Ltd.

Developed and launched a duty and tax engine for e-commerce participants.

  • Sector: Business enterprise software

  • Region: UK: South West

  • Stage: Growth

  • Eligible Tax: EIS

  • Funding: £2,700,000

  • Status: LIVE

13% Funded
READ MORE

Metix Ltd.

Developed a suite of portable, multi-parameter, non-invasive, hand-held emergency vital signs monitors. “Where Emergency Medicine Begins.”

  • Sector: HealthTech

  • Region: Glasgow, Scotland

  • Stage: Growth

  • Eligible Tax: EIS

  • Funding: £1,000,000

  • Status: LIVE

76% Funded
READ MORE

Touch Biometrix Ltd.

“A revolution in Fingerprint Biometrics”

  • Sector: Electronics & Hardware

  • Region: UK: Wales & Netherlands: Eindhoven

  • Stage: Growth – pre-revenue

  • Eligible Tax: EIS

  • Funding: £2,000,000

  • Status: LIVE

33% Funded
READ MORE

Voxsmart Ltd.

Innovative mobile surveillance platform, for the heavily regulated global financial services industry.

  • Sector: RegTech

  • Region: London, UK

  • Stage: Growth

  • Eligible Tax: EIS

  • Funding: £2,100,000

  • Status: LIVE

30% Funded
READ MORE

vTime Holdings Ltd

Vtime

Developed an innovative and multi-user communication, entertainment and engagement platform for VR and AR

  • Sector: Gaming

  • Region: UK: North-West

  • Stage: Growth

  • Eligible Tax: EIS

  • Funding: £1,600,000

  • Status: LIVE

92% Funded
READ MORE

Zilico Ltd.

  • Sector: MedTech

  • Region: UK: North-West

  • Stage: Growth

  • Eligible Tax: EIS

  • Funding: £4,000,000

  • Status: LIVE

19% Funded
READ MORE

Targeted Approach

Deepbridge Syndicate allows eligible investors to invest alongside the highly qualified specialists at Deepbridge into high growth life science and disruptive technology companies.

  • Expertise: Access to Life Sciences and Technology companies who have been through extensive due diligence, leveraging over 200 years combined experience by Deepbridge’s specialist team; investors can be confident of realistic company valuations, market need and potential for growth.

  • Hands-on Management: Deepbridge takes a proactive approach to managing underlying investee companies, taking a board position to ensure they are developing as planned and in the best interest of investors.

  • Online Investment Platform: Investors can build and monitor their own portfolio of high growth companies, with access to company financials, video presentations, regular updates and much more, through their online profile.

  • Tax Efficient Investing: Unless otherwise stated, all companies featuring on Deepbridge Syndicate are EIS eligible, thereby mitigating some of the investment risk for our investors.

  • Investor Fee Free: We do not charge investors any fees at the point of investment, therefore investors enjoy 100% of EIS tax benefits and have 100% of their investment actually put to work earning investment returns.

Providing funding to the companies who are working to improve our lives and the lives of our future generations offers much more than just a financial opportunity.

100% Rule

Deepbridge Syndicate is an investor fee free proposition.

Investors are not charged any fees at the point of investment allowing investors to enjoy 100% of EIS tax benefits and 100% of their investment put to work earning investment returns.

More on Fees

About Deepbridge Syndicate

We want to offer experienced investors the opportunity to make well-informed, personal decisions on which innovative life sciences and disruptive technology companies to invest in, with all the added reassurance brought with specialist, hands-on investment managers.

Investing in Life Sciences

Investing in Life Sciences is different. 

It is not always as obvious to see the exit opportunities, understand the nuances of the technology or value the proposition – but the potential of this sector is considerable.  We think private investors should have the opportunity to get involved at the early stages, support the advancement of healthcare and reap the rewards from this continuously growing sector.

Investing in disruptive technology

Backing companies creating new markets or with potential to displace the incumbent

New technologies are changing how we live and work, how we interact with each other. Deepbridge aims to identify technology growth companies that have a proven technology, robust intellectual property and are operating in a high growth market sector.  Deepbridge believe these companies can typically accelerate rapidly, generating encouraging results within a medium to long-term time frame.

Deepbridge Syndicate has been developed to open up opportunities to individuals which have traditionally have been reserved for institutional investors. By working alongside Deepbridge’s highly experienced specialists, all companies have been through thorough due diligence and valuation by a team with over 200 years worth of combined cross-sector commercial experience, and will have ongoing guidance, mentoring and support from the team for the lifetime of the investment.

To find out more about the team visit here. If you have any questions please don’t hesitate to get in touch.

Meet Our Team

With over 200 years combined experience, the Management team has ultimate responsibility for the management of Deepbridge Syndicate. The Partners will identify, appoint and co-ordinate any necessary employees, contractors and advisers, taking the key commercial and legal decisions and resolving issues to ensure that the strategic expansion is executed efficiently and seamlessly.

Ian Warwick
Ian Warwick
Managing Partner
A successful entrepreneur and CEO with more than two decades of leading private and public companies, Ian has successfully led...
Dr Savvas Neophytou
Dr Savvas Neophytou
Partner, Head of Life Sciences
Savvas is the Head of Life Sciences at Deepbridge. Prior to joining Deepridge, Savvas enjoyed a 15 year career in...
Prof. Chris Wood
Prof. Chris Wood
Senior Medical Adviser
Over 20 years of experience in the biotechnology sector, Chris has founded, managed and successfully exited two biotechnology companies, Bioenvision...
Kieran O’Gorman
Kieran O’Gorman
Technical Partner
With a wealth of experience in financial services, including institutional fund management within the Lloyd’s of London insurance community, and...
Matthias Müller
Matthias Müller
Senior Technology Adviser
As Senior Technology Adviser, Matthias assists in the appraisal and assessment of new technologies, as part of the investment appraisal...
Fuchsia Curry
Fuchsia Curry
Syndicate Manager
Fuchsia manages Deepbridge Syndicate, the online capital raising platform of Deepbridge Capital. With a degree in Financial and Business Economics...
Andrew Aldridge
Andrew Aldridge
Head of Marketing
As Head of Marketing, Andrew oversees all Deepbridge communications and messaging. Andrew has a wealth of experience marketing financial and...
Ray Eugeni
Ray Eugeni
Partner
Ray is an experienced capital markets professional having spent over two decades working for some of the largest banks and...
Adrian Neilan
Adrian Neilan
COO & Investment Director, Technology
With a Masters in Computer Science from Trinity College Dublin and a MBA from Dublin City University, Adrian has considerable...
Prof. Nagy Habib
Prof. Nagy Habib
Supervisory Investment Committee Member – Life Sciences
Nagy Habib is Professor of Hepatobiliary Surgery, at the Department of Cancer Surgery, at Imperial College London. With principal research...
Dr Gary O’Hare
Dr Gary O’Hare
Supervisory Investment Committee Member - Life Sciences
Gary graduated from Trinity College, Dublin with MB BCh BAO, in 1997. Subsequently he undertook training in various medical specialities...
Liz Kirby
Liz Kirby
Supervisory Investment Committee Member – Technology Growth
Liz has a degree in Chemistry and a DPhil in Physical Chemistry from the University of Oxford. She joined the...
Geoff Davison
Geoff Davison
Supervisory Investment Committee Member – Life Sciences
Geoff is the Chief Executive of Bionow, the life sciences membership organisation for the North of England. Having founded the...
Lloyd Price
Lloyd Price
Supervisory Investment Committee Member – Life Sciences
Lloyd co-founded, launched and scaled Zesty from an idea in July 2012 into one of the UK’s leading Digital Health...
Miss Rebecca Roberts
Miss Rebecca Roberts
Supervisory Investment Committee Member - Life Sciences
Rebecca is a paediatric surgeon at the Bristol Royal Hospital for Children.  A member of the Royal College of Surgeons...

We are proud to be working with:

Invest alongside the specialists

Deepbridge Syndicate allows eligible investors to invest alongside the highly qualified life sciences and tech specialists at Deepbridge. Benefiting from Deepbridge’s extensive due diligence and sector knowledge; investors can be confident of realistic company valuations and be reassured by Deepbridge’s proactive ongoing management of investee companies.

Contact Us

This website uses cookies and third party services. Deepbridge Syndicate is designed for non-advised, appropriate investors looking to invest into single EIS-eligible companies, with a minimum investment of £10,000. For persons not meeting this criteria please visit www.deepbridgecapital.com.RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to sell shares; the loss of the value of investment; dilution of shareholding and investing in single company investment should be done only as part of a diversified portfolio. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme. Please read full Risk Warning. By continuing to view this website you are confirming you have read the above notification and risk warning.

Ok